| Q34583106 | 5-HT 1A receptors are reduced in temporal lobe epilepsy after partial-volume correction |
| Q36319893 | 5-HT1A receptor binding in temporal lobe epilepsy patients with and without major depression |
| Q41664217 | 5-HT2 and D2 dopamine receptor occupancy in the living human brain. A PET study with risperidone |
| Q29400289 | A PET study on regional coexpression of 5-HT1A receptors and 5-HTT in the human brain |
| Q57499453 | A Two-Compartment Description and Kinetic Procedure for Measuring Regional Cerebral [11C]Nomifensine Uptake Using Positron Emission Tomography |
| Q33861946 | A comparative evaluation of the dopamine D(2/3) agonist radiotracer [11C](-)-N-propyl-norapomorphine and antagonist [11C]raclopride to measure amphetamine-induced dopamine release in the human striatum |
| Q34635445 | A comparison of the high-affinity peripheral benzodiazepine receptor ligands DAA1106 and (R)-PK11195 in rat models of neuroinflammation: implications for PET imaging of microglial activation |
| Q33695259 | A consistent and efficient graphical analysis method to improve the quantification of reversible tracer binding in radioligand receptor dynamic PET studies |
| Q93527495 | A double-injection technique for in vivo measurement of dopamine D2-receptor density in monkeys with 3-(2'-[18F]fluoroethyl)spiperone and dynamic positron emission tomography |
| Q33851465 | A graphical method to compare the in vivo binding potential of PET radioligands in the absence of a reference region: application to [¹¹C]PBR28 and [¹⁸F]PBR111 for TSPO imaging |
| Q33964638 | A linear model for estimation of neurotransmitter response profiles from dynamic PET data |
| Q48711520 | A method for the quantification of benzodiazepine receptors by using123I-iomazeniI and SPECT with one scan and one blood sampling |
| Q47783539 | A pilot study of serotonergic modulation after long-term administration of oxytocin in autism spectrum disorder |
| Q70963254 | A reappraisal of the relative merits of SPET and PET in the quantitation of neuroreceptors: the advantage of a longer half-life! |
| Q35617870 | A review of graphical methods for tracer studies and strategies to reduce bias |
| Q37214528 | A review of imaging agent development |
| Q71141876 | A simple method for the quantification of benzodiazepine receptors using iodine-123 iomazenil and single-photon emission tomography |
| Q30054735 | A thermostable bacterial cocaine esterase rapidly eliminates cocaine from brain in nonhuman primates |
| Q37838858 | Absolute abundances and affinity states of dopamine receptors in mammalian brain: A review |
| Q43595525 | Absolute quantification by positron emission tomography of the endogenous ligand |
| Q33688285 | Accounting for pharmacokinetic differences in dual-tracer receptor density imaging. |
| Q48260461 | Adaptive-optimal design in PET occupancy studies |
| Q39269129 | Advantages of a dual-tracer model over reference tissue models for binding potential measurement in tumors. |
| Q67898218 | Age-related changes in human D1 dopamine receptors measured by positron emission tomography |
| Q43700713 | Age-related changes of dopamine D1-like and D2-like receptor binding in the F344/N rat striatum revealed by positron emission tomography and in vitro receptor autoradiography |
| Q46816018 | Age-related diurnal effect on D2 receptor binding: a preliminary PET study |
| Q24646913 | Alzheimer disease and cognitive reserve: variation of education effect with carbon 11-labeled Pittsburgh Compound B uptake |
| Q31871442 | Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria. |
| Q47350100 | An open-label positron emission tomography study to evaluate serotonin transporter occupancy following escalating dosing regimens of (R)-(-)-O-desmethylvenlafaxine and racemic O-desmethylvenlafaxine. |
| Q30651933 | Analyses of [(18)F]altanserin bolus injection PET data. II: consideration of radiolabeled metabolites in humans. |
| Q44525601 | Analysis of D2 dopamine receptor occupancy with quantitative SPET using the high-affinity ligand [123I]epidepride: resolving conflicting findings |
| Q48260640 | Analysis of three- and four-compartment models for in vivo radioligand-neuroreceptor interaction |
| Q48125537 | Application of feedback-controlled bolus plus infusion (FC-B/I) method for quantitative PET imaging of dopamine transporters with [(18)F]β-CFT-FE in conscious monkey brain |
| Q42741921 | Approaches to quantify radioligands that wash out slowly from target organs |
| Q36543810 | Approaches to the design of biochemical probes for positron emission tomography |
| Q48354185 | Assessment of dynamic neurotransmitter changes with bolus or infusion delivery of neuroreceptor ligands |
| Q31911220 | Assessment of muscarinic receptor concentrations in aging and Alzheimer disease with [11C]NMPB and PET. |
| Q59845561 | Benzodiazepine Receptor Quantification in vivo in Humans Using [11C]Flumazenil and PET: Application of the Steady-State Principle |
| Q39499651 | Benzodiazepine receptors resolved |
| Q51580734 | Benzodiazepine site pharmacokinetic/pharmacodynamic quantification in man: direct measurement of drug occupancy and effects on the human brain in vivo. |
| Q46807855 | Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. |
| Q34042073 | Black cohosh has central opioid activity in postmenopausal women: evidence from naloxone blockade and positron emission tomography neuroimaging |
| Q34151747 | Brain imaging of 18F-fallypride in normal volunteers: blood analysis, distribution, test-retest studies, and preliminary assessment of sensitivity to aging effects on dopamine D-2/D-3 receptors |
| Q50350029 | Brain neuroreceptor density and personality traits: towards dimensional biomarkers for psychiatric disorders |
| Q37158272 | Brain serotonin transporter binding in depressed patients with bipolar disorder using positron emission tomography |
| Q34619565 | Brain serotonin transporter binding in non-depressed patients with Parkinson's disease |
| Q37980708 | Central benzodiazepine receptor imaging and quantitation with single photon emission computerised tomography: SPECT. |
| Q43694461 | Changes in mACh, NMDA and GABA(A) receptor binding after lateral fluid-percussion injury: in vitro autoradiography of rat brain frozen sections |
| Q46691558 | Changes in thalamus-hypothalamus serotonin transporter availability during clomipramine administration in patients with obsessive-compulsive disorder |
| Q48408268 | Characteristics of specific in vivo labeling of neuroleptic binding sites with 3-N-[11C]methylspiperone |
| Q48101337 | Characterization of [123I]FP-CIT binding to the dopamine transporter in the striatum of tree shrews by quantitative in vitro autoradiography. |
| Q46881449 | Clozapine binds preferentially to cortical D1-like dopamine receptors in the primate brain: a PET study |
| Q42252468 | Cocaine Cue-Induced Dopamine Release in Recreational Cocaine Users |
| Q37486266 | Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition |
| Q48370689 | Comparison of bolus and infusion methods for receptor quantitation: application to [18F]cyclofoxy and positron emission tomography |
| Q90432507 | Comparison of different quantification methods for 18F-fluorodeoxyglucose-positron emission tomography studies in rat brains |
| Q52320706 | Comparison of methods for analysis of clinical [11C]raclopride studies. |
| Q46573123 | Comparison of noninvasive quantification methods of in vivo vesicular acetylcholine transporter using [123I]-IBVM SPECT imaging |
| Q48519346 | Comparison of three 18F-labeled butyrophenone neuroleptic drugs in the baboon using positron emission tomography |
| Q52294820 | Comparison of two binding equations for prediction of the concentration of unbound valproic acid in the serum of adult epileptic polytherapy patients. |
| Q52298616 | Comparison of two compartmental models for describing receptor ligand kinetics and receptor availability in multiple injection PET studies. |
| Q33331804 | Compartmental Analysis of Diprenorphine Binding to Opiate Receptors in the Rat in vivo and its Comparison with Equilibrium Data in vitro |
| Q48669249 | Compartmental analysis of [11C]flumazenil kinetics for the estimation of ligand transport rate and receptor distribution using positron emission tomography |
| Q39694004 | Compartmental model analysis in pharmacokinetics |
| Q68817233 | Concerning strategies for in vivo measurement of receptor binding using positron emission tomography |
| Q68834706 | Concerning strategies for in vivo measurement of receptor binding using positron emission tomography. II |
| Q34630958 | Consensus nomenclature for in vivo imaging of reversibly binding radioligands |
| Q38810544 | Considerations in the Development of Reversibly Binding PET Radioligands for Brain Imaging |
| Q33837669 | Cortical binding of pittsburgh compound B, an endophenotype for genetic studies of Alzheimer's disease |
| Q39948706 | Cumulative input function method for linear compartmental models and spectral analysis in PET |
| Q43784235 | D1 dopamine receptor binding in mood disorders measured by positron emission tomography |
| Q52201849 | Decrease in benzodiazepine receptor binding in a patient with Angelman syndrome detected by iodine-123 iomazenil and single-photon emission tomography. |
| Q67217660 | Decreased [18F]spiperone binding in putamen in idiopathic focal dystonia |
| Q42436209 | Decreased brainstem and putamen SERT binding potential in depressed suicide attempters using [11C]-zient PET imaging |
| Q48800661 | Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. |
| Q48884068 | Delayed image of iodine-123 iomazenil as a relative map of benzodiazepine receptor binding: the optimal scan time |
| Q30597009 | Delivery of imaging agents into brain |
| Q52925137 | Derivation of [(11)C]WAY-100635 binding parameters with reference tissue models: effect of violations of model assumptions. |
| Q41916908 | Derivatives of dibenzothiophene for positron emission tomography imaging of α7-nicotinic acetylcholine receptors |
| Q37572288 | Detection and quantification of opiate receptors in man by positron emission tomography. Potential applications to the study of pain |
| Q55069738 | Determination of binding affinity of molecular imaging agents for steroid hormone receptors in breast cancer. |
| Q44685269 | Determination of volume of distribution using likelihood estimation in graphical analysis: elimination of estimation bias |
| Q38244707 | Development of (18)F-labeled radiotracers for neuroreceptor imaging with positron emission tomography |
| Q48286464 | Development of a method to measure kinetics of radiolabelled monoclonal antibody in human tumour with applications to microdosimetry: positron emission tomography studies of iodine-124 labelled 3F8 monoclonal antibody in glioma |
| Q64243835 | Diagnostic performance of the specific uptake size index for semi-quantitative analysis of I-123-FP-CIT SPECT: harmonized multi-center research setting versus typical clinical single-camera setting |
| Q53428062 | Diet matters: Glucocorticoid-related neuroadaptations associated with calorie intake in female rhesus monkeys. |
| Q68310979 | Difference in in vivo receptor binding between [3 H]N-methylspiperone and [3 H]raclopride in reserpine-treated mouse brain |
| Q49046781 | Differential kinetics of [123I]beta-CIT binding to dopamine and serotonin transporters |
| Q39976098 | Diffusion-limited binding explains binary dose response for local arterial and tumour drug delivery |
| Q47964407 | Distributed versus compartment models for PET receptor studies |
| Q48622208 | Distribution of cortical benzodiazepine receptor binding in right-handed healthy humans: a voxel-based statistical analysis of iodine 123 iomazenil SPECT with partial volume correction |
| Q37188954 | Dopamine D1 receptors in cocaine dependence measured with PET and the choice to self-administer cocaine |
| Q37102424 | Dopamine D2 receptor availability is linked to hippocampal-caudate functional connectivity and episodic memory |
| Q33841939 | Dopamine D2 receptor density in the limbic striatum is related to implicit but not explicit movement sequence learning |
| Q51413531 | Dopamine and serotonin transporters in patients with schizophrenia: an imaging study with [(123)I]beta-CIT. |
| Q33833648 | Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies |
| Q48198394 | Dopamine imaging markers and predictive mathematical models for progressive degeneration in Parkinson's disease. |
| Q48159268 | Dual-isotope autoradiographic measurement of regional blood flow and benzodiazepine receptor availability following unilateral middle cerebral artery occlusion |
| Q47580972 | Dynamic Changes in Striatal mGluR1 But Not mGluR5 during Pathological Progression of Parkinson's Disease in Human Alpha-Synuclein A53T Transgenic Rats: A Multi-PET Imaging Study |
| Q40526470 | EMD 281014, a specific and potent 5HT2 antagonist in humans: a dose-finding PET study |
| Q30422060 | Early AD pathology in a [C-11]PiB-negative case: a PiB-amyloid imaging, biochemical, and immunohistochemical study |
| Q48375763 | Ecstasy-induced reduction of the availability of the brain serotonin transporter as revealed by [11C](+)McN5652-PET and the multi-linear reference tissue model: loss of transporters or artifact of tracer kinetic modelling? |
| Q43651099 | Effect of temperature on serum protein binding characteristics of phenytoin in monotherapy paediatric patients with epilepsy |
| Q51602096 | Effect of unbound clearance on binding parameters of valproic acid to serum proteins. |
| Q34256020 | Effects of Age on Dopamine and Serotonin Receptors Measured by Positron Tomography in the Living Human Brain |
| Q36723875 | Effects of blood flow on [11C]raclopride binding in the brain: model simulations and kinetic analysis of PET data |
| Q44342476 | Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers |
| Q48566169 | Effects of early life stress on [11C]DASB positron emission tomography imaging of serotonin transporters in adolescent peer- and mother-reared rhesus monkeys. |
| Q45068213 | Effects of endogenous dopamine on kinetics of [3H]N-methylspiperone and [3H]raclopride binding in the rat brain |
| Q44642302 | Effects of endogenous dopamine on measures of [18F]N-methylspiroperidol binding in the basal ganglia: Comparison of simulations and experimental results from PET studies in baboons |
| Q73154094 | Effects of estradiol and progesterone administration on human serotonin 2A receptor binding: a PET study |
| Q28212958 | Effects of sex, age, and aggressive traits in man on brain serotonin 5-HT1A receptor binding potential measured by PET using [C-11]WAY-100635 |
| Q47775208 | Effects of the GABAergic system on in vivo binding of [3H]N-methylspiperone |
| Q37383747 | Elevated serotonin 1A binding in remitted major depressive disorder: evidence for a trait biological abnormality |
| Q58751451 | Emerging PET Radiotracers and Targets for Imaging of Neuroinflammation in Neurodegenerative Diseases: Outlook Beyond TSPO |
| Q48752096 | Enhancement of [123I]beta-CIT binding in the striatum with clomipramine: is there a serotonin-dopamine interaction? |
| Q48552371 | Epileptic seizure disorders. Developments in diagnosis and therapy |
| Q49096720 | Equilibrium modeling of 5-HT(2A) receptors with [18F]deuteroaltanserin and PET: feasibility of a constant infusion paradigm |
| Q52048661 | Estimate the time varying brain receptor occupancy in PET imaging experiments using non-linear fixed and mixed effect modeling approach. |
| Q31137052 | Estimating neurotransmitter kinetics with ntPET: a simulation study of temporal precision and effects of biased data |
| Q45774664 | Evaluation of 18F-BCPP-EF for mitochondrial complex 1 imaging in the brain of conscious monkeys using PET. |
| Q48420914 | Evaluation of 75Br-labelled butyrophenone neuroleptics for imaging cerebral dopaminergic receptor areas using positron emission tomography |
| Q35103315 | Evaluation of dopamine D₂/₃ specific binding in the cerebellum for the positron emission tomography radiotracer [¹¹C]FLB 457: implications for measuring cortical dopamine release |
| Q44715102 | Evaluation of safety and tolerability, pharmacokinetics, and pharmacodynamics of BMS-820836 in healthy subjects: a placebo-controlled, ascending single-dose study |
| Q34111552 | Evidence of increased serotonin-1A receptor binding in type 2 diabetes: a positron emission tomography study |
| Q40882172 | Exercise elevates dopamine D2 receptor in a mouse model of Parkinson's disease: In vivo imaging with [18F]fallypride |
| Q35375565 | Extended characterisation of the serotonin 2A (5-HT2A) receptor-selective PET radiotracer 11C-MDL100907 in humans: quantitative analysis, test-retest reproducibility, and vulnerability to endogenous 5-HT tone |
| Q45299934 | Extrastriatal dopamine D(2) receptor binding in Huntington's disease |
| Q30586123 | Functional neuroimaging |
| Q39083974 | Generalized paired-agent kinetic model for in vivo quantification of cancer cell-surface receptors under receptor saturation conditions |
| Q30620159 | Graphical analysis of PET data applied to reversible and irreversible tracers |
| Q34356874 | Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects |
| Q28236042 | Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations |
| Q51620752 | Graphical, kinetic, and equilibrium analyses of in vivo [123I] beta-CIT binding to dopamine transporters in healthy human subjects. |
| Q45942055 | High occupancy of sigma1 receptors in the human brain after single oral administration of donepezil: a positron emission tomography study using [11C]SA4503. |
| Q33976272 | Higher serotonin 1A binding in a second major depression cohort: modeling and reference region considerations |
| Q37829639 | How have developments in molecular imaging techniques furthered schizophrenia research? |
| Q37615648 | How to design PET experiments to study neurochemistry: application to alcoholism |
| Q50890537 | Human 5-HT transporter availability predicts amygdala reactivity in vivo. |
| Q93204051 | Hunting for the high-affinity state of G-protein-coupled receptors with agonist tracers: Theoretical and practical considerations for positron emission tomography imaging |
| Q37647162 | Image-derived arterial input function for quantitative fluorescence imaging of receptor-drug binding in vivo. |
| Q44886306 | Imaging dopamine receptors in the rat striatum with the MicroPET R4: kinetic analysis of [11C]raclopride binding using graphical methods |
| Q43069916 | Imaging endogenous opioid peptide release with [11C]carfentanil and [3H]diprenorphine: influence of agonist-induced internalization |
| Q43721371 | Imaging human mesolimbic dopamine transmission with positron emission tomography: I. Accuracy and precision of D(2) receptor parameter measurements in ventral striatum |
| Q36633126 | Imaging of opioid receptors in the central nervous system |
| Q33993075 | Importance of quantification for the analysis of PET data in oncology: review of current methods and trends for the future |
| Q35664017 | Improved Visualization and Specific Binding for Metabotropic Glutamate Receptor Subtype 1 (mGluR1) Using [11C]ITMM with Ultra-High Specific Activity in Small-Animal PET. |
| Q48271303 | Improved precision of exposure-response relationships by optimal dose-selection. Examples from studies of receptor occupancy using PET and dose finding for neuropathic pain treatment |
| Q71806407 | In Vivo Neuroreceptor Imaging by SPECT in Migraine |
| Q53483950 | In vivo DA D(1) receptor selectivity of NNC 112 and SCH 23390. |
| Q44801609 | In vivo affinity of [18F]fallypride for striatal and extrastriatal dopamine D2 receptors in nonhuman primates. |
| Q41988368 | In vivo and in vitro validation of reference tissue models for the mGluR(5) ligand [(11)C]ABP688. |
| Q49015036 | In vivo binding of spiperone and N-methylspiperone to dopaminergic and serotonergic sites in the rat brain: multiple modeling and implications for PET scanning |
| Q35549386 | In vivo characterization of chronic traumatic encephalopathy using [F-18]FDDNP PET brain imaging. |
| Q30663528 | In vivo imaging of nicotinic receptor upregulation following chronic (-)-nicotine treatment in baboon using SPECT. |
| Q48644876 | In vivo kinetics of [18F](N-methyl)benperidol: a novel PET tracer for assessment of dopaminergic D2-like receptor binding |
| Q44557834 | In vivo measurement of the serotonin transporter with (S)-([18F]fluoromethyl)-(+)-McN5652. |
| Q34170958 | In vivo quantification of monoamine oxidase A in baboon brain: a PET study using [(11)C]befloxatone and the multi-injection approach |
| Q36479293 | In vivo quantification of tumor receptor binding potential with dual-reporter molecular imaging |
| Q44129741 | In vivo receptor assay with multiple ligand concentrations: an equilibrium approach |
| Q48616836 | In vivo saturation kinetics of two dopamine transporter probes measured using a small animal positron emission tomography scanner |
| Q48421523 | Increased occupancy of dopamine receptors in human striatum during cue-elicited cocaine craving |
| Q48559258 | Influence of agonist induced internalization on [3H]Ro15-4513 binding-an application to imaging fluctuations in endogenous GABA with positron emission tomography |
| Q30594766 | Introduction to the analysis of PET data in oncology |
| Q73538624 | Iterative optimal design of PET experiments for estimating beta-adrenergic receptor concentration |
| Q44336021 | Kinetic Analysis of Transport and Opioid Receptor Binding of [3H](−)-Cyclofoxy in Rat Brain in vivo: Implications for Human Studies |
| Q42158298 | Kinetic analysis and test-retest variability of the radioligand [11C](R)-PK11195 binding to TSPO in the human brain - a PET study in control subjects |
| Q48870576 | Kinetic analysis of 3-quinuclidinyl 4-[125I]iodobenzilate transport and specific binding to muscarinic acetylcholine receptor in rat brain in vivo: implications for human studies |
| Q36082764 | Kinetic analysis of [11C]McN5652: a serotonin transporter radioligand |
| Q93519872 | Kinetic analysis of central [11C]raclopride binding to D2-dopamine receptors studied by PET--a comparison to the equilibrium analysis |
| Q48628005 | Kinetic analysis of central [76Br]bromolisuride binding to dopamine D2 receptors studied by PET. |
| Q48882699 | Kinetic evaluation of positron-emitting muscarinic receptor ligands employing direct intracarotid injection |
| Q38195959 | Kinetic modeling in pre-clinical positron emission tomography |
| Q48263640 | Kinetic modeling of receptor-ligand binding applied to positron emission tomographic studies with neuroleptic tracers |
| Q33581200 | Kinetic modeling of the monoamine oxidase B radioligand [¹¹C]SL25.1188 in human brain with high-resolution positron emission tomography |
| Q30785495 | Kinetic modeling without accounting for the vascular component impairs the quantification of [(11)C]PBR28 brain PET data |
| Q33388271 | Kinetic modelling of [11C]flumazenil using data-driven methods |
| Q44454369 | Kinetic modelling of [123I]CNS 1261--a potential SPET tracer for the NMDA receptor |
| Q97544929 | Kinfitr - an open-source tool for reproducible PET modelling: validation and evaluation of test-retest reliability |
| Q36287874 | Large Variation in Brain Exposure of Reference CNS Drugs: a PET Study in Nonhuman Primates |
| Q40730465 | Levodopa effects on [ (11)C]raclopride binding in the resting human brain |
| Q33841668 | Ligand-receptor interactions as studied by PET: implications for drug development |
| Q44426141 | Linear regression with spatial constraint to generate parametric images of ligand-receptor dynamic PET studies with a simplified reference tissue model |
| Q34230368 | Linearized reference tissue parametric imaging methods: application to [11C]DASB positron emission tomography studies of the serotonin transporter in human brain |
| Q47270976 | Loss of D2 receptor binding with age in rhesus monkeys: importance of correction for differences in striatal size |
| Q48361745 | Loss of striatal [76Br]bromospiperone binding sites demonstrated by positron tomography in progressive supranuclear palsy |
| Q35965848 | Low Dopamine D2/D3 Receptor Availability is Associated with Steep Discounting of Delayed Rewards in Methamphetamine Dependence. |
| Q38062257 | Magnetic resonance-guided positron emission tomography image reconstruction |
| Q43851126 | Mapping adenosine A(1) receptors in the cat brain by positron emission tomography with [(11)C]MPDX. |
| Q36083469 | Mapping neuroreceptors at work: on the definition and interpretation of binding potentials after 20 years of progress |
| Q92834619 | Mapping the landscape of human dopamine D2/3 receptors with [11C]raclopride |
| Q52508631 | Maps of receptor binding parameters in the human brain--a kinetic analysis of PET measurements. |
| Q98944880 | Markers for the central serotonin system correlate to verbal ability and paralinguistic social voice processing in autism spectrum disorder |
| Q35662761 | Measurement of 5-HT1A receptor binding in depressed adults before and after antidepressant drug treatment using positron emission tomography and [11C]WAY-100635. |
| Q48253974 | Measurement of benzodiazepine receptor number and affinity in humans using tracer kinetic modeling, positron emission tomography, and [11C]flumazenil |
| Q34170886 | Measurement of density and affinity for dopamine D(2) receptors by a single positron emission tomography scan with multiple injections of [(11)C]raclopride. |
| Q42876675 | Measurement of dopamine D2 receptors in living human brain using [11C]raclopride with ultra-high specific radioactivity |
| Q43976818 | Measurement of dopamine transporter occupancy for multiple injections of cocaine using a single injection of [F-18]FECNT. |
| Q48278378 | Measurement of striatal D2 dopamine receptor density and affinity with [11C]-raclopride in vivo: a test-retest analysis |
| Q52919674 | Measurement of striatal and extrastriatal dopamine D1 receptor binding potential with [11C]NNC 112 in humans: validation and reproducibility. |
| Q46679252 | Measuring SSRI occupancy of SERT using the novel tracer [123I]ADAM: a SPECT validation study |
| Q42414770 | Measuring drug occupancy in the absence of a reference region: the Lassen plot re-visited |
| Q37172834 | Measuring specific receptor binding of a PET radioligand in human brain without pharmacological blockade: The genomic plot |
| Q44848583 | Measuring the in vivo binding parameters of [18F]-fallypride in monkeys using a PET multiple-injection protocol |
| Q44015370 | Modeling [18 F]MPPF positron emission tomography kinetics for the determination of 5-hydroxytryptamine(1A) receptor concentration with multiinjection. |
| Q42621815 | Modeling analysis of [11C]flumazenil kinetics studied by PET: application to a critical study of the equilibrium approaches. |
| Q30623699 | Modeling of PET data in CNS drug discovery and development |
| Q34343207 | Models and methods for derivation of in vivo neuroreceptor parameters with PET and SPECT reversible radiotracers |
| Q46248912 | Models for in vivo kinetic interactions of dopamine D2-neuroreceptors and 3-(2'-[18F]fluoroethyl)spiperone examined with positron emission tomography |
| Q46715544 | Modulation of amphetamine-induced dopamine release by group II metabotropic glutamate receptor agonist LY354740 in non-human primates studied with positron emission tomography |
| Q33668796 | Multi-graphical analysis of dynamic PET. |
| Q51753002 | Multicompartmental analysis of [11C]-carfentanil binding to opiate receptors in humans measured by positron emission tomography. |
| Q60618664 | Multicompartmental study of fluorine-18 altanserin binding to brain 5HT2 receptors in humans using positron emission tomography |
| Q57788867 | Neuroinflammation in schizophrenia: meta-analysis of in vivo microglial imaging studies |
| Q68805724 | Neuroreceptor assay with positron emission tomography: equilibrium versus dynamic approaches |
| Q36314030 | Neuroreceptor imaging in psychiatry: theory and applications. |
| Q35738206 | Neuroreceptor quantitation in vivo by the steady-state principle using constant infusion or bolus injection of radioactive tracers |
| Q47951473 | No serotonin 5-HT2A receptor density abnormality in the cortex of schizophrenic patients studied with PET. |
| Q43820029 | Non-MAO A binding of clorgyline in white matter in human brain |
| Q37888466 | Non-invasive methods to study drug disposition: positron emission tomography. Detection and quantification of brain receptors in man. |
| Q48095488 | Noninvasive estimation of normalized distribution volume: application to the muscarinic-2 ligand [(18)F]FP-TZTP. |
| Q37325526 | Noninvasive k3 estimation method for slow dissociation PET ligands: application to [11C]Pittsburgh compound B. |
| Q37695328 | Noninvasive quantification of metabotropic glutamate receptor type 1 with [¹¹C]ITDM: a small-animal PET study |
| Q30541857 | Noninvasive visualization of human dopamine dynamics from PET images |
| Q57715304 | On the Undecidability among Kinetic Models: From Model Selection to Model Averaging |
| Q31033080 | PET Neurochemical Imaging Modes. |
| Q41986434 | PET analysis of alcohol interaction with the brain disposition of [11C]flumazenil |
| Q38095925 | PET imaging for receptor occupancy: meditations on calculation and simplification |
| Q48475729 | PET imaging of dopamine D2 receptors during chronic cocaine self-administration in monkeys |
| Q36586088 | PET imaging of dopamine receptors in human basal ganglia: relevance to mental illness |
| Q60618609 | PET imaging of garbage protein in Alzheimer’s disease: does it require reappraisal of brain PET analysis? |
| Q37695347 | PET imaging of ischemia-induced impairment of mitochondrial complex I function in monkey brain. |
| Q48320138 | PET measurement of serotonin transporter occupancy: a comparison of escitalopram and citalopram |
| Q34088965 | PET physiological measurements using constant infusion |
| Q43873886 | PET studies of 18F-memantine in healthy volunteers |
| Q48219140 | PET studies of binding competition between endogenous dopamine and the D1 radiotracer [11C]NNC 756. |
| Q68427183 | PET studies of dopamine receptor distribution using [18F]fluoroethylspiperone: findings in disorders related to the dopaminergic system |
| Q36936150 | PET: A biological imaging technique |
| Q39519023 | Pain and opiate receptors: considerations for the design of positron emission tomography studies |
| Q61806902 | Paired-Agent Fluorescence Molecular Imaging of Sentinel Lymph Nodes Using Indocyanine Green as a Control Agent for Antibody-Based Targeted Agents |
| Q43820434 | Parametric images of the extrastriatal D2 receptor density obtained using a high-affinity ligand (FLB 457) and a double-saturation method |
| Q34725750 | Pharmacokinetic imaging: a noninvasive method for determining drug distribution and action |
| Q55515912 | Physiological random processes in precision cancer therapy. |
| Q57004543 | Positron Emission Tomography in Psychopharmacology |
| Q38016654 | Positron emission tomography and cholinergic mechanisms: an overview |
| Q36129732 | Positron emission tomography and single-photon emission computed tomography in central nervous system drug development. |
| Q37123875 | Positron emission tomography applied in the study of pituitary adenomas |
| Q34327907 | Positron emission tomography compartmental models |
| Q37358557 | Positron emission tomography imaging of D(2/3) agonist binding in healthy human subjects with the radiotracer [(11)C]-N-propyl-norapomorphine: preliminary evaluation and reproducibility studies. |
| Q34130175 | Positron emission tomography imaging of dopamine D₂/₃ receptors in the human cortex with [¹¹C]FLB 457: reproducibility studies |
| Q39613753 | Positron emission tomography in movement disorders |
| Q31167584 | Positron emission tomography ligand activation studies in the sports sciences: measuring neurochemistry in vivo |
| Q46900351 | Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease |
| Q43794820 | Positron emission tomography quantification of [(11)C]-DASB binding to the human serotonin transporter: modeling strategies. |
| Q34440136 | Positron emission tomography quantification of [11C]-harmine binding to monoamine oxidase-A in the human brain |
| Q36303529 | Positron emission tomography quantification of serotonin transporter binding in medication-free bipolar disorder |
| Q37049887 | Positron emission tomography quantification of serotonin transporter in suicide attempters with major depressive disorder |
| Q35766460 | Positron emission tomography receptor assay with multiple ligand concentrations: an equilibrium approach |
| Q48854255 | Positron emission tomography studies of neurotransmitter systems |
| Q74233838 | Positron emission tomography study of pindolol occupancy of 5-HT(1A) receptors in humans: preliminary analyses |
| Q44090733 | Positron emission tomography. Progress in brain imaging |
| Q48255308 | Positron tomographic quantitation of neuroreceptors in human brain in vivo--with special reference to the D2 dopamine receptors in caudate nucleus |
| Q38684291 | Possibility of Predicting Serotonin Transporter Occupancy From the In Vitro Inhibition Constant for Serotonin Transporter, the Clinically Relevant Plasma Concentration of Unbound Drugs, and Their Profiles for Substrates of Transporters |
| Q34589414 | Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease |
| Q30419672 | Postpartum and depression status are associated with lower [[¹¹C]raclopride BP(ND) in reproductive-age women |
| Q48767945 | Preclinical evaluation of [123I]R93274 as a SPECT radiotracer for imaging 5-HT2A receptors |
| Q43972774 | Prefrontal dopamine D1 receptors and working memory in schizophrenia. |
| Q51431445 | Presynaptic and postsynaptic dopaminergic binding densities in the nigrostriatal and mesocortical systems in early Parkinson's disease: a double-tracer positron emission tomography study. |
| Q35692936 | Principles of tracer kinetic analysis |
| Q48487572 | Progressive supranuclear palsy: loss of striatal dopamine receptors demonstrated in vivo by positron tomography |
| Q36445693 | Psychosis and positron tomography |
| Q48769578 | Quantification of Human Opiate Receptor Concentration and Affinity Using High and Low Specific Activity [11C]Diprenorphine and Positron Emission Tomography |
| Q48363610 | Quantification of Neuroreceptors in the living human brain. II. Inhibition studies of receptor density and affinity |
| Q48516606 | Quantification of PET studies with the very high-affinity dopamine D2/D3 receptor ligand [11C]FLB 457: re-evaluation of the validity of using a cerebellar reference region |
| Q70168714 | Quantification of baboon cortical S2 serotonin receptors in vivo with 3-N-(2'-F18)fluoroethylspiperone and positron emission tomography |
| Q52880636 | Quantification of benzodiazepine receptors in human brain using PET, [11C]flumazenil, and a single-experiment protocol. |
| Q44848584 | Quantification of cerebral A1 adenosine receptors in humans using [18F]CPFPX and PET. |
| Q48159280 | Quantification of cerebral nicotinic acetylcholine receptors by PET using 2-[18F]fluoro-A-85380 and the multiinjection approach |
| Q44352755 | Quantification of delta-opioid receptors in human brain with N1'-([11C]methyl) naltrindole and positron emission tomography |
| Q47976364 | Quantification of muscarinic cholinergic receptors with [11C]NMPB and positron emission tomography: method development and differentiation of tracer delivery from receptor binding |
| Q41874977 | Quantification of neuroreceptors in the living human brain. I. Irreversible binding of ligands |
| Q41878571 | Quantifying receptor density in vivo using a dual-probe approach with fluorescence molecular imaging |
| Q48212090 | Quantitation of extrastriatal D2 receptors using a very high-affinity ligand (FLB 457) and the multi-injection approach |
| Q35208026 | Quantitation of translocator protein binding in human brain with the novel radioligand [18F]-FEPPA and positron emission tomography |
| Q48152969 | Quantitative PET imaging of radioligands with slow kinetics in human brain. |
| Q46973688 | Quantitative analyses of regional [11C]PE2I binding to the dopamine transporter in the human brain: a PET study |
| Q43937499 | Quantitative analysis for estimating binding potential of the brain serotonin transporter with [11 C]McN5652. |
| Q48548547 | Quantitative analysis for estimating binding potential of the peripheral benzodiazepine receptor with [(11)C]DAA1106. |
| Q41854612 | Quantitative analysis of [11C]AZ10419369 binding to 5-HT1B receptors in human brain |
| Q59845518 | Quantitative analysis of [carbonyl-11C]WAY-100635 PET studies |
| Q44886310 | Quantitative analysis of dopamine D2 receptor kinetics with small animal positron emission tomography |
| Q27023605 | Quantitative in vivo cell-surface receptor imaging in oncology: kinetic modeling and paired-agent principles from nuclear medicine and optical imaging |
| Q37551473 | Quantitative in vivo receptor binding III: Tracer kinetic modeling of muscarinic cholinergic receptor binding |
| Q48710535 | Radiation dosimetry of [18F] (N-methyl)benperidol as determined by whole-body PET imaging of primates. |
| Q39833273 | Radioactive oxygen-15 in the study of cerebral blood flow, blood volume, and oxygen metabolism |
| Q38859451 | Radiosynthesis and in vivo Evaluation of Carbon-11 (2S)-3-(1H-Indol-3-yl)-2-{[(4-methoxyphenyl)carbamoyl]amino}-N-{[1-(5-methoxypyridin-2-yl)cyclohexyl]methyl}propanamide: An Attempt to Visualize Brain Formyl Peptide Receptors in Mouse Models of Neu |
| Q34468544 | Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transporters |
| Q38254737 | Recent advances in parametric neuroreceptor mapping with dynamic PET: basic concepts and graphical analyses |
| Q35024111 | Receptor and transporter imaging studies in schizophrenia, depression, bulimia and Tourette's disorder--implications for psychopharmacology |
| Q48338717 | Reduced brain serotonin transporter availability in major depression as measured by [123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane and single photon emission computed tomography |
| Q48205757 | Reduced midbrain-pons serotonin transporter binding in patients with obsessive-compulsive disorder |
| Q43248340 | Reduced parahippocampal and lateral temporal GABAA-[11C]flumazenil binding in major depression: preliminary results. |
| Q48705214 | Regional brain measurement of Bmax and KD with the opiate antagonist cyclofoxy: equilibrium studies in the conscious rat. |
| Q40445138 | Regional heterogeneity of 5-HT1A receptors in human cerebellum as assessed by positron emission tomography |
| Q69826129 | Regional specific binding of [11C]RO 15 1788 to central type benzodiazepine receptors in human brain: quantitative evaluation by PET |
| Q90732288 | Regional times to equilibria and their impact on semi-quantification of [18F]AV-1451 uptake |
| Q37252773 | Relationship of the serotonin transporter gene promoter polymorphism (5-HTTLPR) genotype and serotonin transporter binding to neural processing of negative emotional stimuli |
| Q43577897 | Reproducibility of in vivo brain measures of 5-HT2A receptors with PET and. |
| Q51072080 | Robust experiment design for estimating myocardial beta adrenergic receptor concentration using PET. |
| Q40139168 | Role of Kinetic Modeling in Biomedical Imaging |
| Q48127572 | SPECT quantification of [123I]iomazenil binding to benzodiazepine receptors in nonhuman primates: I. Kinetic modeling of single bolus experiments |
| Q72376577 | SPECT quantification of [123I]iomazenil binding to benzodiazepine receptors in nonhuman primates: II. Equilibrium analysis of constant infusion experiments and correlation with in vitro parameters |
| Q48616535 | Search for correlations between serotonin 5-HT1A receptor expression and cognitive functions--a strategy in translational psychopharmacology |
| Q42178045 | Selection of weighting factors for quantification of PET radioligand binding using simplified reference tissue models with noisy input functions |
| Q46562388 | Sequential versus nonsequential measurement of density and affinity of dopamine D2 receptors with [11C]raclopride: 2: effects of DAT inhibitors |
| Q44685274 | Sequential versus nonsequential measurement of density and affinity of dopamine D2 receptors with [11C]raclopride: effect of methamphetamine |
| Q48428891 | Serotonin 1A receptor availability in patients with schizophrenia and schizo-affective disorder: a positron emission tomography imaging study with [11C]WAY 100635. |
| Q36696405 | Serotonin 1A receptor reductions in postpartum depression: a positron emission tomography study |
| Q37633750 | Serotonin 2A receptors in obsessive-compulsive disorder: a positron emission tomography study with [11C]MDL 100907. |
| Q73997912 | Serotonin 5-HT2 receptors in schizophrenic patients studied by positron emission tomography |
| Q34305236 | Serotonin 5HT2 receptor imaging in the human brain using positron emission tomography and a new radioligand, [18F]altanserin: results in young normal controls |
| Q40012224 | Serotonin transporter genotype is associated with cognitive performance but not regional 5-HT1A receptor binding in humans |
| Q43700709 | Sex differences in [123I]beta-CIT SPECT measures of dopamine and serotonin transporter availability in healthy smokers and nonsmokers. |
| Q50131292 | Similarity and robustness of PET and SPECT binding parameters for benzodiazepine receptors |
| Q42414714 | Simultaneous estimation of input functions: an empirical study. |
| Q37632839 | Simultaneous measurement of extracellular dopamine and dopamine transporter occupancy by cocaine analogs in squirrel monkeys |
| Q27309046 | Small-animal PET imaging of amyloid-beta plaques with [11C]PiB and its multi-modal validation in an APP/PS1 mouse model of Alzheimer's disease |
| Q42106007 | Social change and access to a palatable diet produces differences in reward neurochemistry and appetite in female monkeys |
| Q46447581 | Specific binding of [3H]pyrilamine to histamine H1 receptors in guinea pig brain in vivo: determination of binding parameters by a kinetic four-compartment model. |
| Q52306514 | Stereotaxic summation analysis of human cerebral benzodiazepine binding maps. |
| Q48361734 | Strategies for in vivo measurement of receptor binding using positron emission tomography |
| Q72635469 | Striatal D2 dopamine receptor binding characteristics in vivo in patients with alcohol dependence |
| Q28551943 | Striatal Dopamine D2/D3 Receptor Availability Is Associated with Executive Function in Healthy Controls but Not Methamphetamine Users |
| Q47778325 | Striatal dopamine D2/3 receptor-mediated neurotransmission in major depression: Implications for anhedonia, anxiety and treatment response |
| Q33656355 | Striatal dopamine d2/d3 receptor availability is reduced in methamphetamine dependence and is linked to impulsivity |
| Q73222431 | Striatal dopaminergic transmission and neocortical glucose utilization in Alzheimer's disease: a triple-tracer positron emission tomography study |
| Q48080738 | Suicidal ideation modulates the reduction in serotonin transporter availability in male military conscripts with major depression: A 4-[18F]-ADAM PET study |
| Q44648588 | Suitability of [18F]altanserin and PET to determine 5-HT2A receptor availability in the rat brain: in vivo and in vitro validation of invasive and non-invasive kinetic models |
| Q41135661 | Swim stress alters in vivo binding of [3H]N-methylspiperone |
| Q37286420 | Synthesis and biological evaluation of novel carbon-11 labeled pyridyl ethers: candidate ligands for in vivo imaging of alpha4beta2 nicotinic acetylcholine receptors (alpha4beta2-nAChRs) in the brain with positron emission tomography |
| Q38828768 | Synthesis, binding affinity, radiolabeling, and microPET evaluation of 4-(2-substituted-4-substituted)-8-(dialkylamino)-6-methyl-1-substituted-3,4-dihydropyrido[2,3-b]pyrazin-2(1H)-ones as ligands for brain corticotropin-releasing factor type-1 (CRF |
| Q38984519 | Tactics for preclinical validation of receptor-binding radiotracers |
| Q37925864 | Technical aspects of amyloid imaging for Alzheimer's disease |
| Q52211022 | Temperature effect on serum protein binding kinetics of phenytoin in monotherapy patients with epilepsy. |
| Q48301045 | Test-retest stability of cerebral A1 adenosine receptor quantification using [18F]CPFPX and PET. |
| Q33478744 | Test-retest variability of high resolution positron emission tomography (PET) imaging of cortical serotonin (5HT2A) receptors in older, healthy adults |
| Q48698421 | The Visualization of Neuronal Benzodiazepine Receptors in the Brain by Autoradiography and Immunohistochemistry |
| Q55332403 | The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models. |
| Q37500893 | The dopaminergic basis of human behaviors: A review of molecular imaging studies |
| Q46984899 | The effect of antiepileptic drugs on 5-HT-receptor binding measured by positron emission tomography |
| Q36094332 | The high affinity peripheral benzodiazepine receptor ligand DAA1106 binds specifically to microglia in a rat model of traumatic brain injury: implications for PET imaging |
| Q36482672 | The high affinity peripheral benzodiazepine receptor ligand DAA1106 binds to activated and infected brain macrophages in areas of synaptic degeneration: implications for PET imaging of neuroinflammation in lentiviral encephalitis |
| Q36677808 | The peripheral benzodiazepine receptor (Translocator protein 18kDa) in microglia: from pathology to imaging |
| Q34343170 | The physical chemistry of ligand-receptor binding identifies some limitations to the analysis of receptor images |
| Q23992160 | The predictive power of brain mRNA mappings for in vivo protein density: a positron emission tomography correlation study |
| Q48902212 | The quantitative analysis of D2-dopamine receptors in baboon striatum in vivo with 3-N-[2'-18F]fluoroethylspiperone using positron emission tomography |
| Q34088959 | The role of model-based methods in the development of single scan techniques |
| Q41676775 | The role of positron emission tomography in pharmacokinetic analysis |
| Q28727519 | The role of serotonin in sleep disordered breathing associated with Parkinson disease: a correlative [11C]DASB PET imaging study |
| Q40515066 | The simplified reference tissue model: model assumption violations and their impact on binding potential. |
| Q47254408 | The tau positron-emission tomography tracer AV-1451 binds with similar affinities to tau fibrils and monoamine oxidases. |
| Q48143122 | Theoretical effects of radioligand diffusional gradients and microscopic neuroreceptor distribution in in vivo kinetic studies |
| Q21136367 | Thinking outside a less intact box: thalamic dopamine D2 receptor densities are negatively related to psychometric creativity in healthy individuals |
| Q37369444 | Tiagabine increases [11C]flumazenil binding in cortical brain regions in healthy control subjects |
| Q35049632 | Tomography of epidermal growth factor receptor binding to fluorescent Affibody in vivo studied with magnetic resonance guided fluorescence recovery in varying orthotopic glioma sizes. |
| Q64080667 | Towards Improved Pharmacokinetic Models for the Analysis of Transporter-Mediated Hepatic Disposition of Drug Molecules with Positron Emission Tomography |
| Q37635268 | Unexpectedly high affinity of a novel histamine H(3) receptor antagonist, GSK239512, in vivo in human brain, determined using PET. |
| Q48404399 | Uptake and utilization of [beta-11C] 5-hydroxytryptophan in human brain studied by positron emission tomography |
| Q34040435 | Use of Positron Emission Tomography to Measure Brain Activity Responses to Fentanyl Analgesia |
| Q36215997 | Uses and Limitations of Positron Emission Tomography in Clinical Pharmacokinetics/Dynamics (Part II) |
| Q36026695 | Using a reference tissue model with spatial constraint to quantify [11C]Pittsburgh compound B PET for early diagnosis of Alzheimer's disease |
| Q52923973 | Validation and reproducibility of measurement of 5-HT1A receptor parameters with [carbonyl-11C]WAY-100635 in humans: comparison of arterial and reference tisssue input functions. |
| Q48548536 | Validation of a tracer kinetic model for the quantification of 5-HT(2A) receptors in human brain with [(11)C]MDL 100,907. |
| Q36666227 | Validation of the reference tissue model for estimation of dopaminergic D2-like receptor binding with [18F](N-methyl)benperidol in humans |
| Q50985041 | Validity of model approximations for receptor-ligand kinetics in nuclear medicine. |
| Q49056581 | Vesicular monoamine transporter concentrations in bipolar disorder type I, schizophrenia, and healthy subjects |
| Q48316857 | Visual evaluation of kinetic characteristics of PET probe for neuroreceptors using a two-phase graphic plot analysis |
| Q48772014 | Visualization and quantification of neurokinin-1 (NK1) receptors in the human brain |
| Q31911300 | [(11)C, (127)I] Altropane: a highly selective ligand for PET imaging of dopamine transporter sites |
| Q33954169 | [(11)]Cocaine: PET studies of cocaine pharmacokinetics, dopamine transporter availability and dopamine transporter occupancy |
| Q28731698 | [11C]flumazenil binding is increased in a dose-dependent manner with tiagabine-induced elevations in GABA levels |
| Q48198612 | [11C]tropanyl benzilate-binding to muscarinic cholinergic receptors: methodology and kinetic modeling alternatives |
| Q32144136 | [123I] beta-CIT and single photon emission computed tomography reveal reduced brain serotonin transporter availability in bulimia nervosa |
| Q48326056 | [123I]-beta-CIT SPECT imaging shows reduced thalamus-hypothalamus serotonin transporter availability in 24 drug-free obsessive-compulsive checkers |
| Q53440586 | [18F]fallypride-PET/CT Analysis of the Dopamine D₂/D₃ Receptor in the Hemiparkinsonian Rat Brain Following Intrastriatal Botulinum Neurotoxin A Injection. |